Composto FDA-regolato
Questo composto è approvato o regolato dall'FDA. L'acquisto senza una prescrizione valida potrebbe violare la legge federale. Verifica tutti i requisiti legali nella tua giurisdizione.
Semaglutide
Ozempic / Wegovy / Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
Meccanismo d'azione
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
Protocolli di ricerca
Solo per scopi di ricerca. Non è consiglio medico.
Typical research protocols use 0.25mg weekly for 4 weeks, escalating to 0.5mg weekly, then 1mg weekly. Maximum studied dose is 2.4mg weekly for weight management.
Note di ricerca
Clinical Research Status
FDA-approved for type 2 diabetes (Ozempic 2017, Rybelsus 2019) and obesity (Wegovy 2021). Ongoing Phase 3 trials for NASH/MASH (liver disease), heart failure with preserved ejection fraction, Alzheimer's disease, and substance use disorders. SELECT trial demonstrated 20% cardiovascular risk reduction in overweight patients.
Key Published Findings
STEP trials demonstrated 15-17% average body weight loss over 68 weeks at 2.4mg weekly dose. SUSTAIN trials showed HbA1c reductions of 1.5-1.8% in type 2 diabetes. PIONEER trials established efficacy of oral formulation. FLOW trial showed 24% reduction in kidney disease progression. STEP HFpEF trial showed significant improvement in heart failure symptoms and physical limitations.
Safety Profile
Most common side effects are gastrointestinal: nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). These typically diminish with dose titration. Black box warning for thyroid C-cell tumors (observed in rodents, not confirmed in humans). Reports of pancreatitis, gallbladder events, and retinopathy complications. Post-marketing reports of suicidal ideation under investigation.
Drug Interactions & Contraindications
Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Delays gastric emptying, which may affect absorption of other oral medications. Caution with insulin or sulfonylureas (increased hypoglycemia risk). Not recommended during pregnancy or breastfeeding.
Comparison to Related Compounds
More potent and longer-acting than liraglutide (Victoza/Saxenda). Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist showing slightly greater weight loss (up to 22.5% in SURMOUNT trials). Retatrutide (triple agonist) in Phase 3 trials shows even greater efficacy. CagriSema (semaglutide + cagrilintide) in Phase 3 trials combines GLP-1 and amylin pathways.
Community Observations
Extreme demand has led to widespread shortages and compounding pharmacy versions of varying quality. Counterfeit products are a significant concern. Users commonly report dramatic appetite suppression, food noise reduction, and altered relationship with alcohol. Muscle loss during weight loss is a frequently discussed concern — resistance training and adequate protein intake are widely recommended.
Semplifichro
~7 days
Riconcimimento
Bacteriostatic water (BAC)
Conservazione
Lyofilizzato
Room temperature up to 36 months. Protect from light.
Riconcimato
Refrigerate 2-8C. Use within 56 days.
Stato legale USA
Anche noto come
Ultima ricerca
Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Domande frequenti
Che cos'è Semaglutide?
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
Come agisce Semaglutide?
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
Qual è lo stato normativo di Semaglutide negli Stati Uniti?
FDA-approved (Rx only)
Qual è l'emivita di Semaglutide?
~7 days
Con quali altri nomi è noto Semaglutide?
Ozempic, Wegovy, Rybelsus
Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.
Leggi l'intera dichiarazione di responsabilità